Search results
Showing 651 to 700 of 1835 results for carers
LAM-561 with radiotherapy and temozolomide for treating IDH1 wild-type glioblastoma [ID4022]
Awaiting development Reference number: GID-TA11741 Expected publication date: TBC
Awaiting development Reference number: GID-TA11753 Expected publication date: TBC
In development Reference number: GID-TA11850 Expected publication date: 03 September 2026
PXT3003 for treating Charcot-Marie-Tooth disease type 1A in people aged 16 and over [ID1439]
Awaiting development Reference number: GID-TA11325 Expected publication date: TBC
permanency (incorporating the perspectives of lookedafter children and permanency carers)? Any explanatory notes(if applicable) For a...
This indicator covers the percentage of patients diagnosed with dementia whose care plan has been reviewed in a face-to-face review in the preceding 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM107
In development Reference number: GID-TA11229 Expected publication date: TBC
Awaiting development Reference number: GID-TA11040 Expected publication date: TBC
This quality standard covers the initial management of self-harm and the provision of longer-term support for children and young people (aged 8 to 18) and adults (aged 18 and over) who self-harm. It describes high-quality care in priority areas for improvement.
View quality statements for QS34Show all sections
Sections for QS34
- Quality statements
- Quality statement 1: Compassion, respect and dignity
- Quality statement 2: Initial assessments
- Quality statement 3: Psychosocial assessments
- Quality statement 4: Observation
- Quality statement 5: Safe physical environments
- Quality statement 6: Care plans
- Quality statement 7: Psychological interventions
This quality standard covers care for adults before, during and after primary elective hip, knee or shoulder joint replacement. It describes high-quality care in priority areas for improvement. It does not cover joint replacement as treatment for primary or secondary cancer affecting the bones.
View quality statements for QS206Show all sections
Sections for QS206
- Quality statements
- Quality statement 1: Preoperative rehabilitation advice for hip and knee replacement
- Statement 2: Choice between partial and total knee replacement
- Statement 3: Tranexamic acid during hip and knee replacement
- Quality statement 4: Preventing implant selection errors
- Statement 5: Postoperative rehabilitation
- Update information
- About this quality standard
Awaiting development Reference number: GID-TA11469 Expected publication date: TBC
Abatacept for treating active idiopathic inflammatory myopathies [TSID10095]
Awaiting development Reference number: GID-TA10993 Expected publication date: TBC
Awaiting development Reference number: GID-TA11784 Expected publication date: 21 July 2027
Awaiting development Reference number: GID-TA11748 Expected publication date: TBC
Awaiting development Reference number: GID-TA11769 Expected publication date: TBC
Surgical insertion of a catheter-based intravascular microaxial flow pump for cardiogenic shock
In development Reference number: GID-IPG10461 Expected publication date: 25 March 2026
Awaiting development Reference number: GID-TA11490 Expected publication date: TBC
Question Is a group-based parent training intervention for parents or carers of autistic children and young people clinically and cost...
Pembrolizumab with BCG for treating high-risk non-muscle-invasive bladder cancer [ID6271]
Awaiting development Reference number: GID-TA11300 Expected publication date: TBC
Selpercatinib for untreated RET-positive advanced thyroid cancer [ID6183]
In development Reference number: GID-TA11160 Expected publication date: TBC
In development Reference number: GID-TA11425 Expected publication date: TBC
Awaiting development Reference number: GID-TA11494 Expected publication date: TBC
Awaiting development Reference number: GID-TA11326 Expected publication date: TBC
Awaiting development Reference number: GID-TA11137 Expected publication date: TBC
Awaiting development Reference number: GID-TA11840 Expected publication date: TBC
Zanubrutinib for untreated chronic lymphocytic leukaemia [ID5079]
In development Reference number: GID-TA10966 Expected publication date: TBC
Awaiting development Reference number: GID-TA11673 Expected publication date: TBC
In development Reference number: GID-TA11085 Expected publication date: TBC
Benralizumab for treating hypereosinophilic syndrome in people 12 years and over [ID6322]
Awaiting development Reference number: GID-TA11360 Expected publication date: TBC
Alpelisib for treating severe PIK3CA-related overgrowth spectrum in people 2 years and over [ID6252]
Awaiting development Reference number: GID-TA11284 Expected publication date: TBC
In development Reference number: GID-TA10960 Expected publication date: TBC
Awaiting development Reference number: GID-TA11863 Expected publication date: TBC
Adalimumab for treating early Dupuytren's contracture [ID6276]
Awaiting development Reference number: GID-TA11363 Expected publication date: TBC
Awaiting development Reference number: GID-TA11835 Expected publication date: TBC
In development Reference number: GID-TA11862 Expected publication date: TBC
Awaiting development Reference number: GID-TA11828 Expected publication date: TBC
In development Reference number: GID-TA11718 Expected publication date: TBC
This quality standard covers the routine antenatal care that women and their babies should receive during pregnancy. It describes high-quality care in priority areas for improvement.
View quality statements for QS22Show all sections
Sections for QS22
- Quality statements
- Quality statement 1: Access to antenatal care
- Quality statement 2: Risk assessment
- Quality statement 3: Continuity of carer
- Quality statement 4: Vaccination
- Quality statement 5: Referral for stop-smoking support and treatment
- Quality statement 6: Healthy eating in pregnancy
- Update information
In development Reference number: GID-TA10726 Expected publication date: 13 May 2026
Daratumumab for treating high-risk smouldering multiple myeloma [ID6214]
Awaiting development Reference number: GID-TA11198 Expected publication date: TBC
Mental health of adults in contact with the criminal justice system (QS163)
This quality standard covers recognising, assessing and managing mental health problems in adults (aged 18 and over) who are in contact with the criminal justice system (this includes police contact, court and prison custody, street triage, liaison and diversion services, and probation services). It describes high-quality care in priority areas for improvement.
View quality statements for QS163Show all sections
In development Reference number: GID-TA11615 Expected publication date: TBC
Awaiting development Reference number: GID-TA11811 Expected publication date: TBC
In development Reference number: GID-IPG10318 Expected publication date: 25 March 2026
Percutaneous insertion of a catheter-based intravascular microaxial flow pump for cardiogenic shock
In development Reference number: GID-IPG10404 Expected publication date: 25 March 2026
In development Reference number: GID-TA11801 Expected publication date: TBC
In development Reference number: GID-TA11866 Expected publication date: TBC
Awaiting development Reference number: GID-TA11703 Expected publication date: 25 February 2026
Ranibizumab port delivery system for treating diabetic macular oedema [ID6137]
Awaiting development Reference number: GID-TA11065 Expected publication date: TBC
Odevixibat for treating progressive familial intrahepatic cholestasis (HST17)
Evidence-based recommendations on odevixibat (Bylvay) for treating progressive familial intrahepatic cholestasis in people 6 months and older.